

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces 2025

Half Year Results

Beijing, China, August 23, 2025 LEPU Medical Technology(Beijing) Co., Ltd. (the “Company”) today announced its performance for the six months ended June 30, 2025:

- During the reporting period, the Company achieved operating revenue of RMB 3,369.3846 million, representing a 0.43% year-on-year decrease; net profit attributable to shareholders of the listed company of RMB 690.9259 million, reflecting a 0.91% year-on-year decline; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of RMB 662.1958 million, marking a 2.33% year-on-year growth; and net cash flow from operating activities of RMB 636.3645 million, showing a 300.52% year-on-year increase.
- The medical device segment is the largest revenue-generating segment in the company's business. Its sub-segments mainly include cardiovascular interventional implants, in vitro diagnostics, and surgical anesthesia, with cardiovascular interventional implants being the company's core business segment. During the reporting period, this segment achieved an operating revenue of RMB 1,776.4694 million, a year-on-year increase of 1.30%.
- The pharmaceutical segment generated operating revenue of RMB 1,117.4431 million, reflecting a 1.52% year-on-year decrease but a 79.34% quarter-on-quarter increase, as retail channel inventory clearance was largely completed, with non-atorvastatin calcium and clopidogrel bisulfate products gradually gaining share in the revenue structure. Within this segment, formulated drugs (generics) achieved revenue of RMB 975.3454 million, up 3.89% year-on-year and 107.59% quarter-on-quarter, while API revenue totaled RMB 142.0977 million, down 27.44% year-on-year and 7.28% quarter-on-quarter.
- During the reporting period, the medical services and health management segment achieved operating revenue of RMB 475.4721 million, representing a year-on-year decrease of 4.05%. The Company provides cardiovascular disease medical services and health management through specialized cardiovascular hospitals, medical diagnostic laboratories, and pharmaceutical/medical device e-commerce platforms. Hefei Cardiovascular Hospital generated revenue of RMB 83.4410 million, up 3.51% year-on-year. In health management, the Company's AI-powered business, leveraging the Lepu Cloud Platform, focuses on three major services: medical-grade cardiac monitoring, home-based health monitoring, and smart rehabilitation care, offering various vital sign monitoring products and services to hospitals and individual consumers. The Company's AI-ECG-based vital sign monitoring product portfolio is comprehensive, enabling multiple functions including dynamic ECG, static ECG, bedside monitoring, and wearable telemetry, which not only enhances hospital informatization

to improve diagnostic efficiency but also facilitates convenient home-based vital sign monitoring for patients. Lepu Cloud Intelligence Technology recorded revenue of RMB 284.3827 million, reflecting an 8.46% year-on-year increase.

Financial Results (unaudited)

	Current reporting period	Same period of previous year	Changes compared to previous year (%)
Operating revenue (RMB)	3,369,384,556.21	3,383,886,554.54	-0.43%
Net profit attributable to shareholders of the listed company (RMB)	690,925,899.89	697,242,271.91	-0.91%
Net profit attributable to shareholders of the listed company after deducting nonrecurring profits and losses (RMB)	662,195,779.67	647,147,330.31	2.33%
Net cash flows from operating activities (RMB)	636,364,548.11	158,886,015.01	300.52%
Basic earnings per share (RMB/share)	0.3748	0.3766	-0.48%
Diluted earnings per share (RMB/share)	0.3748	0.3766	-0.48%
Weighted average return on net assets	4.43%	4.47%	-0.04%
	End of reporting period	End of previous year	Changes compared to the end of previous year
Total assets (RMB)	25,358,932,186.53	24,573,100,199.19	3.20%
Net assets attributable to shareholders of the Company (RMB)	15,796,888,042.42	15,201,421,378.82	3.92%

Full semi-annual report

The full semi-annual report as of and for the six months ended June 30, 2025 is available on our website at <https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology (Beijing) Co., Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions. Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.